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Abstract
Background Mitogen-activated protein kinases (MAPKs)
are signalling transduction molecules that have different
functions and diverse behaviour in cancer. In breast cancer,
MAPK is related to oestrogen receptor (ER) and HER2.
Methods Protein expression of a large panel of MAPKs
(JNK1/2, ERK, p38, C-JUN and ATF2 including phos-
phorylated forms) were assessed immunohistochemically
in a large (n = 1400) and well-characterised breast cancer
series prepared as tissue microarray. Moreover, reverse
phase protein array was applied to quantify protein
expression of MAPKs in six breast cancer cell lines with
different phenotypes including HER2-transfected cells.
Results MAPKs expression was associated with clinico-
pathological variables characteristic of good prognosis.
These associations were most significant in the whole
series and in the ER? subgroup compared to other BC
classes. Most of MAPKs showed a positive association
with ER, BCL2 and better outcome and were negatively
associated with the proliferation marker Ki67 and p53.
Association of MAPK with HER2 was mainly seen in the
ER- subgroup. Reverse phase protein array confirmed
immunohistochemistry results and revealed differential
expression of MAPK proteins in ER? and ER- cell lines.
Conclusions MAPKs are associated with good prognosis
and their expression is mainly related to ER. Studying a
large panel rather than individual biomarkers may provide
improved understanding of the pathway.
Keywords MAPK signalling pathways  Reverse phase
protein microarray (RPPA)  Breast cancer
Introduction
Mitogen-activated protein kinases (MAPKs) are evolu-
tionary conserved enzymes which function as signal
transduction pathways that regulate fundamental cell
activities including gene expression, cellular processes
such as growth, proliferation, differentiation, migration and
apoptosis. MAPKs’ stimulation starts from stimulation of
receptor tyrosine kinase (RTK) by growth factors, cytoki-
nes, heat shock, mitogen, osmotic stress or stress factors
[1]. Stimulated receptors associate with certain adaptor
proteins that in turn enhance the recruitment of guanine
nucleotide exchange factors (GEFs) in the cell membrane.
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The latter can stimulate some small GTPase proteins (H-
RAS, N-RAS and K-RAS) which eventually regulate the
switch from GDP to GTP and vice versa [2]. GEFs can
enhance the formation of RAS GTP which is the active
form that can bind to different downstream proteins such as
RAF, members of PI3K pathway and RAL-GEF–RAL
cascade [3–5]. RAF proteins directly phosphorylate
MEK1/2 [6, 7] and can activate ERK1/2 [6] which subse-
quently can enhance different factors such as transcription
factors, kinases and phosphatases [2, 6].
Several groups of MAPK family have been identified,
including extracellular regulatory kinase (ERK1/2/5, also
known as classical MAPK), p38 MAPK and c-Jun N-ter-
minal kinase/stress-activated protein kinases (JNK1/2/3/
SAPKs). Activation of each group requires dual phospho-
rylation of threonine and tyrosine within the activation loop
of the MAPK through a three-tiered cascade composed of
MAPK, MAPK kinases (MEKs) and MAPKKK. MEKs are
specific for each isoform of MAPK family. For instance,
ERK1/ERK2 is activated by MEK1 and MEK2, JNK is
activated by MEK4 and MEK7 and p38 MAPK is activated
by MEK3 and MEK6 [8, 9].
The function of MAPKs in breast cancer (BC) is com-
plex due to different responses they modulate and their
interaction with different pathways [9–11]. MAPKs have
been investigated in BC including their interaction with
oestrogen receptor (ER) and HER2; however, conflicting
results were reported and the exact role of MAPKs in BC
and their interaction with ER and HER2 remain to be
determined [12–14].
The aim of this study is to investigate the role of MAPK
signalling cascade in BC utilising a large panel of biomarker
and a large well-characterised series of early stage BC pre-
pared as TMA using IHC. MAPK expression was assessed in
the different molecular classes based on expression of ER and
HER2 status. In addition, reverse phase protein array (RPPA)
was employed to quantifyMAPK protein expression levels in
different BC cell line phenotypes including the impact of
HER2 transfection in the ER? and ER- cell lines. This ret-
rospective study adheres to REMARK criteria [15].
Materials and methods
In this study, 1400 cases of unselected operable invasive BC
series were included; these are part of the Nottingham Ten-
ovus primary BC series that were enrolled to City Hospital in
the period from 1988 to 1998. All patients’ information was
available including age (\70 years, mean = 55 years),
menopausal status, tumour characteristics (grade, lymph
node stage and size), vascular invasion and Nottingham
prognostic index (NPI) [16]. The management protocol was
uniform and included systemic hormonal therapy for those
whose NPI was [3.4, and if they were premenopausal,
Zoladex was added. The remaining ER-negative cases
received chemotherapy in the form of cyclophosphamide,
methotrexate and 5-fluorouracil.
The regular follow-up was collected and included BC-
specific survival (time from the surgery until the patient die
from or with BC with follow-up period of 15 years. Locore-
gional recurrence data were also available in this series. In
addition, data on a large number of relevant biomarkers were
also available as previously described [17–21].
Immunohistochemistry (IHC)
IHC staining for different MAPK markers was done using
4 lm sections from TMA blocks as published before [22].
Details of primary antibodies and other relevant
biomarkers included in this study are available in Online
Resource. These biomarkers were used to molecularly
characterise the series and further assess the biological
function of MAPK activation in BC.
Scoring of IHC
TMA slides were manually scored using high-resolution
digital images (NanoZoomer, Hamamatsu Photonics,
Welwyn Garden City, UK) scanned at 920 magnification,
by using a web-based interface (Distiller, Slidepath Ltd.,
Dublin, Ireland). H-score and percent were used to score
the markers. The median scores and X-tile bioinformatics
software (version 3.6.1, 2003–2005, Yale University, USA
(http://x-tile.software.informer.com) were both used to
derive optimal cut-off points for each marker [23].
In vitro study
The expression of MAPKs and the interaction with ER and
HER2 were evaluated in six different molecular classes of
BC cell lines which included the following Wild-type
MCF-7 (ER?/HER2-), MDA-MB-231 (ER-/HER2-),
SKBR3 (ER-/HER2?) and BT474 (ER?/HER2?) and
were obtained from the American Type Culture Collection
(Manassas, VA, USA). In addition, MCF-7 (ER?) and
MDA-231 (ER-) were stably transfected with HER2 gene
to assess the impact of HER2 on MAPK activation in BC in
relation to ER status [24]. The HER2 transfection has been
confirmed by WB (Online Resource).
Reverse phase protein microarray (RPPA)
RPPA has been established before [25–28]. In this study,
lysates from the six used BC cell lines were used to eval-
uate the expression of MAPK signalling intermediates. All
primary antibodies were evaluated for specificity using
458 Breast Cancer Res Treat (2016) 159:457–467
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Table 1 The associations between MAPKs and clinicopathological variables in breast cancer
Pan ERK1/2 Nuclear p-ERK1/2 Cytoplasmic-p-ERK1/2
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
Grade
1 85 (14) 99 (17) 0.031 54 (9) 118 (20) <0.0001 52 (10) 119 (20) 0.001
2 199 (32) 203 (36) 156 (28) 241 (41) 172 (32) 220 (36)
3 338 (54) 268 (47) 352 (63) 235 (39) 310 (58) 271 (44)
Lymph node stage
1 379 (61) 343 (60) 0.085 343 (61) 118 (20) NS 313 (58) 384 (63) NS
2 180 (29) 188 (33) 170 (30) 241 (41) 164 (31) 178 (29)
3 63 (10) 40 (7) 49 (9) 235 (39) 57 (11) 48 (8)
Tumour size
\2 CM 290 (47) 301 (53) 0.029 242 (43) 324 (54) <0.0001 222 (42) 336 (55) <0.0001
[2CM 334 (53) 269 (47) 321 (57) 272 (46) 312 (58) 277 (45)
Lymphovascular invasion
No 399 (65) 381 (67) 357 (64) 399 (67) 322 (61) 425 (70) 0.001
Definite 219 (35) 190 (33) NS 202 (36) 192 (33) NS 210 (39) 181(30)
NPI
GPG 170 (28) 183 (34) 0.015 121 (23) 209 (37) <0.0001 122 (24) 205 (35) <0.0001
MPG 324 (54) 293 (54) 314 (59) 293 (51) 286 (56) 317 (54)
PPG 106 (18) 66 (12) 101 (19) 70 (12) 104 (20) 64 (11)
Pan JNK1/2 p-JNK1/2 Pan p38
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
Grade
1 100 (17) 104 (19) NS 26 (11) 131 (16) <0.0001 26 (11) 131 (16) 0.002
2 216 (36) 168 (32) 45 (20) 308 (37) 45 (20) 308 (37)
3 277 (47) 260 (49) 156 (69) 388 (50) 156 (69) 388 (50)
Lymph node stage
1 398 (65) 356 (65) NS 140 (62) 498 (60) NS 140 (62) 498 (60) NS
2 169 (8) 150 (27) 66 (29) 260 (32) 66 (29) 260 (32)
3 46 (7) 42 (8) 21 (9) 69 (8) 21 (9) 69 (8)
Tumour size
\2 CM 283 (50) 274 (55) 0.079 93 (40) 427 (52) 0.003 93 (40) 427 (52) NS
[2 CM 286 (50) 223 (45) 137 (60) 401 (48) 137 (60) 401 (48)
Lymphovascular invasion
No 376 (67) 344 (69) NS 153 (67) 540 (66) NS 153 (67) 540 (66) NS
Definite 187 (33) 152 (31) 76 (33) 282 (34) 76 (33) 282 (34)
NPI
GPG 192 (33) 181 (35) NS 47 (21) 255 (32) 0.002 47 (21) 255 (32) 0.013
MPG 303 (53) 266 (52) 132 (60) 435 (55) 132 (60) 435 (55)
PPG 79 (14) 69 (13) 42 (19) 103 (13) 42 (19) 103 (13)
p-p38 p–C-JUN p-ATF2
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
Grade
1 120 (13) 82 (21) <0.0001 62 (14) 135 (16) <0.0001 114 (12) 81 (24) <0.0001
2 293 (31) 166 (43) 119 (26) 313 (38) 303 (32) 139 (42)
3 525 (56) 142 (36) 268 (60) 380 (46) 539 (56) 114 (34)
Lymph node stage
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Western blotting before using in RPPA as described before
[22, 25].
Statistical analysis
The statistical analysis was performed using Statistical
Package for Social Sciences SPSS v21. Chi-square test was
used to test the associations between categorical data.
Kaplan–Meier test was used for univariate analysis. Krus-
kal–Wallis test was used to test the associations for the
results of RPPA. Moreover, Spearman’s rank correlations
were used. A two-tailed p value of less than 0.05 was
considered significant for all the used statistical tests.
Results
MAPK expression in BC tissue
In this study, 16 MAPKs members were investigated.
Specificity of MAPKs proteins was confirmed by Western
blot which revealed specific band for each protein (Online
Resource). IHC staining of MAPKs (pan and phosphory-
lated (p) ERK1/2, pan JNK1/2, p-JNK1/2, pan p38, p-p38,
p-ATF2 and p-C-JUN) revealed nuclear expression of
phosphorylated proteins except p-ERK1/2 which showed
both nuclear and cytoplasmic expression. The total/un-
phosphorylated forms showed cytoplasmic expression. All
MAPKs proteins showed an equivocal expression in nor-
mal breast tissue, DCIS and BC tissue included within the
TMA cores at varying degrees ranging from negative to
strong positivity (Online Resource).
Cut-off of positivity was chosen for each marker to
assess its association with other variables. There were
positive correlations between different members of
MAPKs using continuous data as well as dichotomised
variables (Online Resource).
The association between MAPKs
and clinicopathological variables
Expression of MAPK proteins showed positive correlations
with clinicopathological features characteristic of good
prognosis including lower grade, early stage, smaller
tumour size, absent lymphovascular invasion and lower
NPI scores (Table 1).
The association between MAPKs and key BC
biomarkers
There was significant correlation with ER and HER2 in
addition to other key BC biomarkers including the prolif-
eration marker KI67-LI and the apoptosis markers BCL2
and p53 (Table 2). Pan ERK1/2 showed strong positive
association with ER and BCL2 but only showed borderline
negative association with KI67-LI and p53. p-ERK1/2 was
Table 1 continued
p-p38 p–C-JUN p-ATF2
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
1 550 (59) 261 (67) 0.008 266 (59) 517 (62) NS 571 (60) 208 (62) NS
2 310 (33) 96 (24) 143 (32) 251 (30) 311 (32) 92 (28)
3 78 (8) 34 (9) 40 (9) 61 (8) 74 (8) 35 (10)
Tumour size
\2 CM 423 (45) 225 (58) <0.0001 206 (46) 421 (51) 0.080 451 (47) 173 (52) NS
[2 CM 517 (55) 166 (42) 245 (54) 408 (49) 507 (53) 162 (48)
Lymphovascular invasion
No 602 (65) 284 (73) 0.002 278 (62) 566 (69) 0.015 611 (64) 234 (71) 0.032
Definite 332 (35) 104 (27) 171 (38) 258 (31) 344 (36) 98 (29)
NPI
GPG 235 (26) 159 (43) <0.0001 114 (26) 264 (33) 0.001 240 (26) 132 (41) <0.0001
MPG 508 (57) 177 (47) 238 (55) 426 (54) 530 (58) 143 (45)
PPG 156 (17) 38 (10) 84 (19) 100 (13) 149 (16) 44 (14)
p values in bold denote significant ones (\0.050), borderline: (0.05–0.09), NS:[0.09) and the same in all tables
NPI Nottingham prognostic index, GPG good prognostic group, MPG moderate prognostic group, PPG poor prognostic group
460 Breast Cancer Res Treat (2016) 159:457–467
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Table 2 Associations between MAPKs and biological markers in the whole series
Pan ERK1/2 Nuclear p-ERK1/2 Cytoplasmic-p-ERK1/2
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
ER
Negative 176 (28) 112 (20) <0.0001 186 (33) 102 (17) <0.0001 146 (28) 139 (23) 0.066
Positive 444 (72) 460 (80) 373 (67) 487 (83) 385 (72) 468 (77)
HER2
Negative 516 (87) 480 (87) NS 443 (83) 516 (90) <0.0001 442 (86) 506 (86) NS
Positive 75 (13) 70 (13) 93 (17) 58 (10) 71 (14) 79 (14)
KI67-LI
Low 200 (39) 208 (46) 0.050 153 (34) 224 (47) <0.0001 159 (37) 233 (47) 0.003
High 307 (61) 247 (54) 304 (66) 250 (53) 266 (63) 263 (53)
P53
Negative 400 (68) 405 (73) 0.064 361 (68) 416 (74) 0.032 351 (69) 416 (72) NS
Positive 185 (32) 147 (27) 172 (32) 149 (26) 160 (31) 158 (28)
BCL2
Negative 199 (47) 134 (32) <0.0001 113 (37) 77 (24) <0.0001 174 (46) 183 (41) NS
Positive 225 (53) 283 (68) 196 (63) 239 (76) 208 (54) 269 (59)
Pan JNK1/2 p-JNK1/2 Pan p38
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
ER
Negative 130 (22) 149 (28) 0.015 94 (41) 189 (23) <0.0001 221 (31) 89 (19) <0.0001
Positive 466 (78) 382 (72) 136 (59) 633 (77) 492 (69) 387 (81)
HER2
Negative 478 (88) 406 (85) 0.092 184 (83) 690 (87) NS 594 (88) 385 (87) NS
Positive 63 (12) 73 (15) 37 (17) 103 (13) 81 (12) 59 (13)
KI67-LI
Low 199 (44) 172 (45) NS 58 (31) 292 (44) 0.001 594 (88) 385 (87) 0.058
High 255 (56) 213 (55) 127 (69) 368 (56) 81 (12) 59 (13)
P53
Negative 394 (74) 331 (69) NS 149 (68) 563 (72) NS 460 (69) 331 (74) 0.060
Positive 141 (26) 149 (31) 70 (32) 222 (28) 205 (31) 113 (26)
BCL2
Negative 150 (38) 183 (48) 0.004 90 (52) 247 (41) 0.005 224 (46) 114 (34) 0.001
Positive 246 (62) 197 (52) 82 (48) 368 (59) 259 (54) 221 (66)
p-p38 p–C-JUN p-ATF2
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
ER
Negative 246 (26) 70 (18) 0.002 130 (29) 178 (22) 0.005 260 (27) 51 (15) 0.003
Positive 692 (74) 317 (82) 321 (71) 645 (78) 693 (73) 281 (85)
HER2
Negative 777 (86) 329 (89) NS 371 (86.3) 687 (86.5) NS 777 (85) 299 (92) 0.001
Positive 128 (14) 42 (11) 59 (13.7) 107 (13.5) 138 (15) 25 (8)
KI67-LI
Low 292 (39) 161 (53) <0.0001 127 (35.6) 304 (45.8) 0.002 289 (38) 144 (53) <0.0001
High 463 (61) 142 (47) 230 (64.4) 360 (54.2) 466 (62) 130 (47)
P53
Negative 637 (70) 267 (73) NS 302 (70.2) 564 (71.5) NS 634 (70) 243 (76) 0.025
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positively associated with ER and negatively with BCL2
but only its nuclear form showed a positive association
with BCL2 and a negative association with HER2 and p53.
Pan JNK1/2 was associated with downregulation of ER and
BCL2; however, its phosphorylated form was associated
with increased expression of ER, BCL2 and with down-
regulation of KI67-LI. p-p38 and its total form were pos-
itively associated with ER and BCL2 and negatively with
KI67-LI.
p-ATF2 and p-C-JUN, which are downstream markers
of the MAPK pathway, showed positive associations with
ER and negative association with KI67-LI. p-ATF2 also
showed positive association with BCL2 and negative with
HER2 and p53.
Within ER? tumours, most of the associations observed
in the whole series remained significant including nuclear
p-ERK1/2, p-p38 and p-ATF2 (Table 3). When the ER?
group was further stratified based on HER2 expression,
some associations were maintained in the ER?/HER2-
subgroup (Online Resource) but not in the ER?/HER2?
tumours. Interestingly, when the analysis was restricted to
HER2- tumours, the associations observed in the whole
cohort and in the ER? class were maintained (Online
Resource). Importantly, when the analysis was restricted to
ER- class, pan-ERK1/2 and p-p38 were associated posi-
tively with HER2 (p = 0.006, 0.003 respectively; Online
Resource).
Outcome analysis
Univariate survival analyses revealed that MAPKs (pan
ERK1/2, nuclear p-ERK1/2, p-JNK1/2, p-p38, p-C-JUN
and p-ATF2) were associated with better outcome in terms
of prolonged BCSS (Fig. 1). ERK1/2 and N-p-ERK1/2
showed better associations with prolong survival within
ER?BC (Fig. 2).
Proteomic analysis of BC cell lines
RPPA was consistent with IHC results and confirmed that
MAPK expression was higher in ER? compared to ER-
cell lines and in the ER?/HER2- cell lines compared to
ER?/HER2?. In the ER- cell lines, there was a trend
towards positive correlation between MAPs and HER2
expression. Interestingly, most of these MAPKs showed
higher expression in ER?HER2- compared to
ER-HER2- cell line.
For example, there was a significant increase in the
expression of p-C-RAF in ER?HER2- (MCF-7) cell line
compared to ER?HER2? transfected (T) while in the
ER- cell lines there was high expression of this protein in
ER-HER2? cell line compared to ER-HER2- and the
difference between these two cell lines was statistically
significant. Regarding MEK1/2, which is the downstream
mediator of p-C-RAF, the same association was noticed.
Similarly, ERK1/2 which is the downstream mediator of
MEK1/2, showed an increase in its expression in
ER?HER2- compared to ER?HER2? and high expres-
sion in ER-HER2? (W and T) compared to ER-HER2-
cell lines (Fig. 3). The details for the expression of all the
MAPK markers are shown in (Online Resource), with all
the p values for the comparison of the expression levels
between the different cell lines.
Discussion
Several studies have emphasised the role of MAPKs in
cancer progression [13, 29–31]. The functions of MAPKs
in BC appear to be complex owing to several cellular
responses that they modulate and their interaction with
different pathways including the key BC genes ER and
HER2. In the current study, the role of MAPKs in BC and
how the expression of ER and HER2 might influence their
function were investigated using a large panel of MAPK
proteins and the results were validated in vitro using
RPPA and different BC cell lines. The results showed that
generally most of MAPKs are associated with good
prognostic features in the whole series and in the ER?
tumours. MAPKs are mainly related to ER expression and
this finding was observed using IHC and validated by
RPPA.
Our results are consistent with others [32] who
demonstrated that ERK1/2 and p-ERK1/2 were associated
Table 2 continued
p-p38 p–C-JUN p-ATF2
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
Positive 269 (30) 97 (27) 128 (29.8) 225 (28.5) 277 (30) 76 (24)
BCL2
Negative 297 (43) 99 (36) 0.037 138 (43.5) 249 (41.2) NS 305 (44) 84 (34) 0.009
Positive 391 (57) 177 (64) 179 (56.5) 355 (58.8) 396 (56) 163 (66)
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with good clinicopathological variables and that by Hsu
et al. [33] who found that p-ERK1/2 is required for
inducing apoptosis especially in MCF-7 and MDA-231 cell
lines. The association between MAPKs and good
prognostic variable may be related to their roles in inducing
apoptosis. p-JNK1/2 also has been shown to be stimulated
by stress or growth factors and either one can enhance
p-JNK1/2 to stimulate apoptosis [34] and even p-JNK1/2
Table 3 Associations between MAPK and biological markers in ER-positive tumours
Pan ERK1/2 N-p-ERK1/2 C-p-ERK1/2
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
HER2
Negative 379 (89) 407 (92) NS 315 (87) 440 (93) 0.005 337 (90) 409 (91) NS
Positive 46 (11) 37 (8) 47 (13) 34 (7) 38 (10) 42 (9)
KI67-LI
Low 179 (50) 190 (52) NS 137 (45) 216 (55) 0.005 141 (46) 211 (55) 0.010
High 180 (50) 174 (4.8) 171 (55) 175 (45) 169 (54) 170 (45)
P53
Negative 325 (77) 364 (82) 0.093 282 (79) 368 (79) NS 291 (78) 351 (79) NS
Positive 96 (23) 81 (18) 76 (21) 99 (21) 81 (22) 92 (21)
BCL2
Negative 101 (33) 81 (23) 0.005 105 (36) 87 (25) 0.001 95 (33) 95 (27) NS
Positive 206 (67) 269 (77) 186 (64) 267 (75) 191 (67) 254 (73)
Pan JNK1/2 p-JNK1/2 Pan p38
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
HER2
Negative 386 (91) 313 (90) NS 115 (87) 553 (91) NS 434 (92) 328 (90) NS
Positive 36 (9) 33 (10) 17 (13) 57 (9) 35 (8) 36 (10)
KI67-LI
Low 185 (53) 152 (54) NS 48 (44) 265 (53) 0.098 208 (53) 158 (52) NS
High 164 (47) 127 (46) 61 (56) 237 (47) 187(47) 144 (48)
P53
Negative 338 (80) 267 (7.8) NS 108 (83) 475 (78) NS 373 (81) 295 (81) NS
Positive 83 (20) 76 (22) 22 (17) 131 (22) 88 (19) 69 (19)
BCL2
Negative 85 (27) 84 (31) NS 36 (33) 131 (28) NS 105 (31) 66 (24) 0.057
Positive 231 (73) 186 (69) 73 (67) 342 (72) 237 (69) 211 (76)
p-p38 p–C-JUN p-ATF2
Low N (%) High N (%) p value Low N (%) High N (%) p value Low N (%) High N (%) p value
HER2
Negative 593 (88) 283 (95) 0.001 273 (89) 563 (90) NS 594 (89) 256 (94) 0.010
Positive 78 (12) 15 (5) 32 (11) 59 (10) 73 (11) 15 (6)
KI67-LI
Low 264 (47) 147 (60) 0.001 113 (44) 277 (54) 0.011 256 (47) 136 (58) 0.003
High 295 (53) 97 (40) 143 (56) 237 (46) 292 (53) 97 (42)
P53
Negative 533 (80) 236 (79) NS 248 (81) 488 (79) NS 523 (79) 523 (79) NS
Positive 135 (20) 61 (21) 58 (19) 128 (21) 140 (21) 140 (21)
BCL2
Negative 162 (31) 50 (23) 0.026 71 (30) 136 (29) NS 153 (29) 55 (27) NS
Positive 360 (69) 168 (77) 163 (70) 333 (71) 368 (71) 151 (73)
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augments cell death signalling in slowly growing MCF-7
cells under the influence of high estradiol level [35].
Interestingly, a drug ‘‘pseudolaric acid B’’ whose function
mimics the upstream mediators of MAPKs was used in an
in vitro experiment and this revealed the apoptotic function
of JNK and its phosphorylated form upon activation [36].
Moreover, several studies have demonstrated the role of
p-p38/MAPK in inducing apoptosis in BC and some sug-
gested that this effect is mediated by TGF-b [37–40].
p-ATF2 is thought to have dual functions independent of
each other; the first is a tumour suppressor protein and the
other function is related to DNA damage response pathway
[41] and importantly, the former function has been con-
firmed by different studies [38, 42, 43]. The above results
regarding the association between MAPKs and apoptosis
were supported by our findings that MAPKs were posi-
tively associated with ER, BCL2 and negatively with
HER2 (or no association with some of them), KI67-LI and
p53.
Consistent with previous studies that assessed the
prognostic value of individual MAPK members
[32, 43, 44], in this study we identified an association
between MAPKs proteins and better outcome in terms of
longer survival time. Importantly, in the current research,
pan ERK1/2 and p-ERK1/2 showed an association with
better outcome in patients with ER? tumours who are
candidate for endocrine therapy. Consistent with this,
Busch et al. [45] have demonstrated that high p-ERK1/2
was an independent predictor of better outcome in
tamoxifen-treated patients. Thus, this study implies that
MAPKs could be prospective surrogate biomarkers in
assessing benefit from endocrine therapy.
In the current study, RPPA results were consistent with
IHC findings for those proteins used in both techniques and
the findings were also consistent for those MAPK members
that were used only in RPPA. In the ER-/HER2? cell line
and in line with our results, a previous study demonstrated
that activation of MAPK is associated with loss of ER
phenotype especially in those overexpressing HER2 [46].
Ostrakhovitch et al. [47] have found that in MDA-231 cell
line where p53 is mutated or suppressed, the phosphory-
lation of ERK1/2 was strong. Meanwhile, p-p38 overex-
pression in ER- tumours is thought to be associated with
proliferation and progression of cancer. This is attributed to
the fact that p-p38 can mediate proliferation only in BC
cells that express mutant p53 and not the wild one, a
finding commonly seen in ER- tumours rather than ER?
tumours [48]. Interestingly, Creighton et al. [49] indicated
that hyperactivation of MAPK leads to the loss of ER
expression and plays a role in the generation of the ER-
Fig. 1 This Kaplan–Meier survival curve illustrates that MAPK members including the nuclear p-ERK1/2, its total form ERK1/2, p-JNK1/2,
p-p38 and the two transcription factors p-C-JUN and p-ATF2 are all associated significantly with prolonged BCSS in the whole series
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Fig. 2 Kaplan–Meier survival
curve showing the associations
of MAPKs (nuclear (N)p ERK1/
2 and pan ERK1/2 are
associated significantly with
prolonged BCSS in ER-positive
series
Fig. 3 Heat-map showing different MAPK pathway intermediates
studied in six different breast cancer cell lines. Rows represent the
different signalling molecules studied. White and red denote markers
that are present at lower and higher levels, respectively. II: Bar
graphs representing measurement of selected target proteins from the
heat-map data, including a ERK1/2, b pERK1/2, c pCRAF and
d pMKK1/2. Data are shown as individual sample data (mean of four
technical replicates per sample) of three different experiments. Signal
represents arbitrary fluorescence units; AFU, after background
subtraction and normalisation to b-actin. Significance values were
derived using the Kruskal–Wallis test
Breast Cancer Res Treat (2016) 159:457–467 465
123
negative phenotype. Although our study supports the dif-
ferential expression of MAPKs between ER? and ER-
phenotypes, it indicates that MAPKs play an important role
in ER? tumours and that their expression in ER? tumours
is associated with better outcome. Supporting this, Ata-
naskova et al. [50] have indicated that activation of ER by
MAPK enhances the expression of ER-regulated genes,
accelerates tumour growth, and that MAPK/ER crosstalk
enhances ER-mediated signalling without diminishing
sensitivity to the inhibitory effects of anti-estrogens.
However, in the ER-negative subgroup, it has been repor-
ted that the oncogenic effect of MAPKs is related to HER2
overexpression [49], which further support our findings.
The role of MAPKs in enhancing cell cycle arrest is also
encountered. This has been attributed to the fact that innate
tumour suppressor mechanisms are activated in response to
aberrant oncogenic stimulation and remarkably induce growth
inhibition that is referred to as oncogenic-induced senescence
[51, 52]. In addition, accumulating evidencehas demonstrated
that sequestration of cytoplasmic ERK in the cytoplasm
induced by proapoptotic molecules such as death-associated
protein kinase could ultimately augment the apoptotic action
of these proapoptotic proteins [53]. In this regard, a study
revealed that feedback inhibitory signals are common from
mutated RAS and RAF to the upstreammediators, which will
omit further stimulation through this pathway being
thoughtfully mediated by HDM2 and FOXO3 [54]. The pre-
vious findings might explain why high expression of MAPKs
in ER? tumours was associated with good features and out-
come in our IHC findings and why the function is different in
ER ? andER- cell lines byusingRPPA. In addition, another
reason which can explain the dual behaviour of theseMAPKs
is that they function in a cell context-specific and cell type-
specificway tomediate signals that can lead to diverse cellular
functions. Furthermore, the function of these MAPKs is
influenced by their crosstalk and interaction with other path-
ways which can influence their behaviour [9–11].
Despite the limitations of this study and type of tech-
niques employed, the findings of this study collectively
together with other previous publications mentioned above
support the tumour suppressor role of MAPK kinase
pathway in BC and that active pathway is associated with
variables of good prognosis and better outcome. In addi-
tion, our results provide further evidence that ER is the
main player related to the function of MAPK in BC;
however, when HER2 is overexpressed, the role of ER
becomes less significant and there is some evidence that
HER2 can play a major role in controlling the MAPK
pathway activation in ER-negative tumours.
In conclusion, our study illustrated the role of MAPKs
and their signalling in BC and demonstrated that MAPKs
are associated with good prognostic features and show
differential expression within ER? and ER- groups.
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